Abnormal Involuntary Movement Scale (AIMS)

12-item scale to assess severity of dyskinesias

The global unit selector only affects unanswered questions
1.Muscles of facial expression
2.Lips and perioral area
3.Jaw
4.Tongue
5.Upper (arms, wrists, hands, fingers)
6.Lower (legs, knees, ankles, toes)
7.Neck, shoulders, hips
8.Severity of abnormal movements
9.Incapacitation due to abnormal movements
10.Patient’s awareness of abnormal movements
11.Current problems with teeth and/or dentures?
12.Does patient usually wear dentures?
Created by

1. Muscles of facial expression

More Information

e.g., movements of forehead, eyebrows, periorbital area, cheeks. Include frowning, blinking, grimacing of upper face.

Created by
0/12 completed

About this Calculator

The Abnormal Involuntary Movement Scale (AIMS) was developed by the Psychopharmacology Research Branch of the National Institute of Mental Health and is one of the most widely used questionnaires for dyskinesias. The AIMS can be readily administered in a few minutes, by an experienced clinician ideal for patients receiving medications that may cause Tardive Dyskinesias.

Part of the AIMS assessment includes observation of the patient under specific examination procedures, which must be followed. Patients may suppress movements while concentrating intensely. Therefore, administration of the AIMS can be supplemented by requesting that the patient perform additional tasks during the assessment.

In general the AIMS is regularly assessed after administration of medications, the time course of abnormal movements may be regularly recorded and plotted. The total score on the AIMS test is not reported to the patient. A rating of two or higher is evidence of tardive dyskinesia. The AIMS test is considered extremely reliable when it is given by experienced raters.

References

Gharabawi GM, Bossie CA, Lasser RA, Turkoz I, Rodriguez S, Chouinard G.

Abnormal Involuntary Movement Scale (AIMS) and Extrapyramidal Symptom Rating Scale (ESRS): cross-scale comparison in assessing tardive dyskinesia.

Schizophr Res. 2005;77(2-3):119-28.

Legal Notices and Disclaimer

© 2020 QxMD Software Inc., all rights reserved. No part of this service may be reproduced in any way without express written consent of QxMD. This information should not be used for the diagnosis or treatment of any health problem or disease. This information is not intended to replace clinical judgment or guide individual patient care in any manner. Click here for full notice and disclaimer.